AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35263755
Drug: Daily somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily somatropin therapy
Trial: 33050945
Drug: Famotidine 160
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Famotidine 160 mg four times a day for up to 14 days
Trial: 33050945
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in the same dosage as Famotidine
Trial: 35956324
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran (30 g/d, containing DF 8.9 g)
Trial: 32020530
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg once daily (QD)
Trial: 32020530
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg twice daily
Trial: 33811803
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of medication programme
Trial: 33811803
Drug: Routine medication
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine medication administration (Control)
Trial: 32020567
Drug: Chemotherapy (imatinib,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (imatinib, bevacizumab)
Trial: 32020567
Drug: Aggressive multi-modality
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive multi-modality treatment options
Trial: 35364066
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy for H pylori eradication (n=817)
Trial: 35364066
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy for H pylori eradication (n=625 with successful eradication)
Trial: 35364066
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy for H pylori eradication (n=625)
Trial: 37258943
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g whole almonds daily during the intervention period
Trial: 33122092
Drug: Sleep Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep Deprivation Treatment (SDT) for 48 hours
Trial: 35477594
Drug: d-Amphetamine Transdermal
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine Transdermal System (d-ATS) 5 mg/9 h, with possible dose increase to 10 mg/9 h, 15 mg/9 h, and 20 mg/9 h during the study
Trial: 35477594
Drug: d-Amphetamine Transdermal
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-Amphetamine Transdermal System (d-ATS)
Trial: 35122668
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation at a dose of 400 IU/d (vD-400 group)
Trial: 36303179
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) at a rate of 60 L/min and a concentration of 100% (n = 87)
Trial: 36303179
Drug: Facemask at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facemask at a rate of 6 L/min and a concentration of 100% (n = 89)
Trial: 33472722
Drug: Whole grain
RxNorm normalized name: Whole grain barley
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole grain intake (half of grain servings from whole grain foods daily for 6 weeks)
Trial: 34347945
Drug: Anti-TNF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF treatment (both etanercept and adalimumab)
Trial: 33481484
Drug: CBD oil
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD oil (150 mg POST, 24 h, 48 h)
Trial: 33346061
Drug: Participants' satisfaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants' satisfaction with treatment results
Trial: 35693874
Drug: Nonavalent HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonavalent HPV vaccine
Trial: 34144047
Drug: Vedolizumab IV
RxNorm normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vedolizumab IV 300 mg every 8 weeks
Trial: 33573589
Drug: Journeying through
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Journeying through Dementia (JtD) intervention, consisting of both group and individual sessions, with a therapeutic dose of 10 out of 16 sessions.
Trial: 35061237
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing probiotics and botanical extract (group II)
Trial: 35061237
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (group II)
Trial: 35238144
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% w/w finasteride spray (1-4 sprays; 50-200 μl/day) for 24 weeks
Trial: 35238144
Drug: Once-daily finasteride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily finasteride 1 mg oral tablet for 24 weeks
Trial: 35238144
Drug: Twice-daily finasteride
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily finasteride 1% topical gel for 6 months
Trial: 35238144
Drug: Once-daily finasteride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily finasteride 1 mg oral tablet for 6 months
Trial: 35238144
Drug: Twice-daily finasteride
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily finasteride 0.25% topical solution for 7 days
Trial: 32295716
Drug: Bivalirudin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (bolus 0.75 mg/kg followed by an infusion 1.75 mg/kg/h for the duration of the procedure)
Trial: 32295716
Drug: Heparin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (bolus 70 U/kg)
Trial: 34050877
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate administration
Trial: 34050877
Drug: No potassium
RxNorm normalized name: No potassium hemofiltration solution
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No potassium citrate administration (Control)
Trial: 32616589
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg·day‐1)
Trial: 32791690
Drug: Digital storytelling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital storytelling intervention based on rational emotive behaviour therapy (REBT)
Trial: 34658006
Drug: Sarilumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab plus usual care (including corticosteroids at 1 mg/kg/day for at least 3 days)
Trial: 34658006
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care alone (including corticosteroids at 1 mg/kg/day for at least 3 days)
Trial: 35557479
Drug: Pregabalin 50
RxNorm normalized name: pregabalin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 50 mg three times a day
Trial: 35557479
Drug: Ketotifen 1
RxNorm normalized name: ketotifen 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 1 mg twice a day
Trial: 34253208
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with paclitaxel plus cisplatin for two cycles followed by radical hysterectomy and bilateral adnexectomy
Trial: 34253208
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with radical surgery
Trial: 32188988
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate plus prednisone (1000 mg/day and 5 mg/day respectively)
Trial: 34981483
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg per 12 hours)
Trial: 37133765
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy–Bladder Cancer (FACT-BL)
Trial: 32951013
Drug: Vasopressin infusion
RxNorm normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasopressin infusion at a mean dose of 0.3 ± 0.2 mU/kg/min
Trial: 34780705
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (0.5 mL injection administered on day 1, month 2, and month 6)
Trial: 33706033
Drug: CAM-ICU assessments
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM-ICU assessments twice daily for 5 days
Trial: 33706033
Drug: CAM-ICU assessments
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM-ICU assessments twice daily for 4 days
Trial: 33706033
Drug: CAM-ICU assessments
RxNorm normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAM-ICU assessments twice daily for 3 days
Trial: 33222472
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (40 Gy in 15 fractions) concomitantly with temozolomide (TMZ) followed by adjuvant TMZ
Trial: 32675772
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg plus Rilpivirine 25 mg (early-switch group)
Trial: 32675772
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg plus Rilpivirine 25 mg (late-switch group)
Trial: 33693741
Drug: Galacto-Oligosaccharides (GOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto-Oligosaccharides (GOS) with iron fortified maize porridge (5 mg iron as FeFum + NaFeEDTA)
Trial: 33693741
Drug: Galacto-Oligosaccharides (GOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto-Oligosaccharides (GOS) with iron fortified maize porridge (5 mg iron as FeSO4)
Trial: 33693741
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified maize porridge (5 mg iron as FeFum + NaFeEDTA) without GOS
Trial: 33693741
Drug: Iron fortified
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron fortified maize porridge (5 mg iron as FeSO4) without GOS
Trial: 34304674
Drug: Mogamulizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (1.0 mg/kg intravenously weekly)
Trial: 34304674
Drug: Vorinostat (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (400 mg orally daily)
Trial: 35891246
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of CoronaVac® with 14 days between doses
Trial: 35891246
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of CoronaVac® with 28 days between doses
Trial: 32891160
Drug: Gum Arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum Arabic (GA) 30-grams-dose once daily for four weeks
Trial: 32891160
Drug: Placebo (pectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (pectin powder 1-gram-dose once daily for four weeks)
Trial: 33952313
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual by the GP
Trial: 33619667
Drug: Life-Sustaining Treatment
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-Sustaining Treatment (LST) for severe disability scenario
Trial: 33619667
Drug: Life-Sustaining Treatment
RxNorm normalized name: Life-O-Gen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Life-Sustaining Treatment (LST) for vegetative state scenario
Trial: 32144926
Drug: Head-nine-needle therapy
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head-nine-needle therapy
Trial: 32144926
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine control (epiperisone hydrochloride and fluoguili hydrochloride)
Trial: 33376120
Drug: One-week interval
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-week interval oral health intervention
Trial: 33376120
Drug: Two-week interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-week interval oral health intervention
Trial: 34454817
Drug: Primary stenting,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary stenting, best medical treatment (BMT) and exercise advice (stent group)
Trial: 34454817
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (BMT) and exercise advice alone (control group)
Trial: 33941629
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (upper limb immobilisation in long arm cast for 4 weeks)
Trial: 34338389
Drug: Increasing buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing buprenorphine-naloxone (BUP-NX) dose in response to opioid use
Trial: 34338389
Drug: Constant buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant buprenorphine-naloxone (BUP-NX) dose after week 2
Trial: 35614586
Drug: Neuromobilisation along
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromobilisation along with conservative treatment (ultrasound therapy, wrist splinting, tendon-gliding exercises)
Trial: 35614586
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (ultrasound therapy, wrist splinting, tendon-gliding exercises)
Trial: 32517847
Drug: DBV712 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBV712 250 µg
Trial: 35164720
Drug: IPSRT-CR (Interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPSRT-CR (Interpersonal and Social Rhythm Therapy with Cognitive Remediation)
Trial: 35164720
Drug: IPSRT (Interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPSRT (Interpersonal and Social Rhythm Therapy) alone
Trial: 35818122
Drug: Intensive arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive arm (8 phone sessions + 8 weeks of nicotine patches)
Trial: 35818122
Drug: Minimal arm
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal arm (3 phone sessions + 2 weeks of nicotine patches)
Trial: 32374959
Drug: Endovascular thrombectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular thrombectomy preceded by intravenous alteplase (0.9 mg/kg within 4.5 hours after symptom onset)
Trial: 32374959
Drug: Combination-therapy group
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination-therapy group (thrombectomy with alteplase)
Trial: 35565845
Drug: Beet It
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beet It Sport® plus 200 mg vitamin C
Trial: 35565845
Drug: Beet It
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beet It Sport® plus 15 g of whey protein
Trial: 35565845
Drug: Beet It
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beet It Sport® (all treatments)
Trial: 34687316
Drug: Rituximab (500mg)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (500mg) with 12 months of antithyroid drug (ATD)
Trial: 35002984
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no metformin therapy)
Trial: 35439582
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure control (combination of perindopril‐indapamide)
Trial: 35701080
Drug: Virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual reality modulator and silicone suture pads (group B)
Trial: 33388987
Drug: Potassium‐competitive acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium‐competitive acid blocker (P‐CAB)
Trial: 33388987
Drug: Serotonin noradrenaline
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin noradrenaline reuptake inhibitor (SNRI)
Trial: 32546262
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics plus orally administered DBT for 10 days
Trial: 32546262
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics plus placebo for 10 days
Trial: 32546262
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics plus orally administered DBT
Trial: 32546262
Drug: Intravenous antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous antibiotics plus placebo
Trial: 35322978
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow MSCs injection
Trial: 32399578
Drug: Zinc oxide
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide treatment
Trial: 35072641
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (6 weekly sessions, with telephone support)
Trial: 35144952
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists)
Trial: 35463906
Drug: L:R (lactulose:rhamnose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L:R (lactulose:rhamnose)
Trial: 35463906
Drug: L:M (lactulose:mannitol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L:M (lactulose:mannitol)
Trial: 32729586
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g intragastric tryptophan (Trp)
Trial: 35460310
Drug: Angelica gigas
RxNorm normalized name: ANGELICA GIGAS ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angelica gigas Nakai root extracts (ARE) lotion
Trial: 35897370
Drug: Clonazepam 0.5
RxNorm normalized name: clonazepam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam 0.5 mg for 4 weeks
Trial: 34551225
Drug: mRNA‐1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA‐1273 vaccine (100 ?g)
Trial: 35958596
Drug: sIPV +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sIPV + DTaP concomitant administration
Trial: 32003357
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy (Group A)
Trial: 33501972
Drug: Antibiotic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribing at visits that met criteria (205/214)
Trial: 33501972
Drug: Antibiotic prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescribing at visits that did not meet criteria (193/211)
Trial: 33834628
Drug: Remibrutinib (0.5‒600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remibrutinib (0.5‒600 mg)
Trial: 33834628
Drug: Remibrutinib (>=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remibrutinib (>= 10 mg q.d.)
Trial: 33834628
Drug: Remibrutinib (>=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remibrutinib (>= 50 mg q.d.)
Trial: 33834628
Drug: Remibrutinib (>=
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remibrutinib (>= 100 mg q.d.)
Trial: 32173730
Drug: Intravenous Tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Tranexamic Acid (TXA) 1-g dose prior to skin incision and another 1-g dose 4 hours later
Trial: 34187822
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for MSF
Trial: 34187822
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment for MSF
Trial: 33497293
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg · kg−1)
Trial: 36123569
Drug: Neuromuscular blockade
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuromuscular blockade (NMB) agent
Trial: 33565308
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) with low dose prednisolone